The potential role of oligo-fucoidan as a bioactive adjunct in oncology: a personal view on mechanistic insights and therapeutic continuity
{{output}}
Despite the evolution of targeted therapies, the clinical efficacy of multimodal treatments is frequently constrained by a persistent 'therapeutic ceiling', where dose-limiting toxicities necessitate involuntary interruptions in 20%-25% of patients. These di... ...
